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췌장암의 항암치료와 방사선 치료 최신 지견
연세대학교 의과대학 소화기내과학교실
성민제·방승민
Updates of Chemotherapy and Radiotherapy for Pancreatic Cancer
Min Je Sung, Seungmin Bang
Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
Pancreatic cancer is still one of the most aggressive malignancy, showing 10% of 
5-year survival. Among the several reasons of the grave prognosis, the poor response 
to chemotherapeutic agents and the absence of effective tool for early detection 
are the most important. Regarding treatments, surgical resection is still positioned 
as the only one for expecting the cure of pancreatic cancer. However, the rate of 
recurrence after surgery is still high as more than 50%. And the portion of patients 
who are diagnosed at the resectable stage is still less than 15% of all cases. So, 
chemotherapy and radiotherapy are the main players for combating with pancreatic 
cancer. After the introduction of outcomes of FOLFIRINOX, and gemcitabine/nab-
paclitaxel for metastatic pancreatic cancer, two-digit overall survival can be expected. 
And, neoadjuvant treatments including concurrent chemoradiation therapy for 
borderline resectable pancreatic cancer and/or resectable pancreatic cancer are 
reported as superior to upfront surgery. More recently, several target agents including 
polyadenosine diphosphate-ribose polymerase inhibitors and immunologic drugs are 
under evaluation for pancreatic cancer. So, herein, current status of chemotherapy and 
radiation therapy for pancreatic cancer will be addressed.
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INTRODUCTION
Pancreatic cancer is still one of the most aggressive malig-
nancies, showing 10% of 5-year survival.1,2 The poor response to 
chemotherapeutic agents and the absence of effective tool for 
early detection are the most important reasons of the grave 
prognosis. Even though surgical resection is the only way to cure 
the disease, the number of patient suitable for surgery at initial 
diagnosis is less than 15% of all cases.1-4 And furthermore, more 
than 50% of the patients who received curative resection should 
enface recurrence of the pancreatic cancer.5-8 However, intro-
duction of neoadjuvant therapy including chemotherapy and/or 
radiation therapy, surgical outcomes become better than 
before. And more effective chemotherapeutic regimens like 
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FOLFIRINOX and nab-paclitaxel with gemcitabine can elongate 
the survival of advanced, metastatic conditions.9,10 More recently, 
several target agents including polyadenosine diphosphate-ribose 
polymerase (PARP) inhibitors and immunologic drugs are 
under evaluation for pancreatic cancer.
MAIN BODY
1. The role of chemotherapy
1) Adjuvant chemotherapy
Even with microscopically complete (R0) resections, recur-
rence rates are very high in pancreatic cancer. Therefore, 
additional adjuvant therapy is required for all patients with 
resected pancreatic adenocarcinoma. From early 1980s, there 
are several milestone studies for adjuvant chemotherapy of 
resected pancreatic cancer (Table 1).11-19 Especially, the European 
Study Group for Pancreatic Cancer (ESPAC-1) and CONKO 
(Charité Onkologie)-001 trial proved the benefit of adjuvant 
chemotherapy with gemcitabine or 5-fluorouracil (5-FU) plus 
leucovorin after curative surgery.13,14 In 2004, final data of 
ESPAC-1 was reported.13 They used 2×2 factorial design to 
randomize 289 patients to either chemotherapy with 5-FU/
leucovorin or no chemotherapy, and chemoradiotherapy with 
20 Gy dose in 10 daily fractions plus 5-FU or no chemoradi-
ation. The overall survival of chemotherapy with 5-FU/
leucovorin group was significantly better than no chemo-
therapy group (HR 0.71; 95% CI 0.55–0.92; p=0.009). With 
this study, adjuvant chemotherapy was turned out to be 
effective and beneficial. In 2007, Oettle et al.14 reported a 
randomized controlled trial-CONKO-001 with gemcitabine 
monotherapy versus observation after curative surgery. In 
this study, disease free survival was significantly longer in 
gemcitabine monotherapy group compared to observation 
group (13.4 vs. 6.9 months). However, median overall survival 
was comparable in both group (22.1 vs. 20.2 months). Based 
on this study, gemcitabine monotherapy has been regarded as 
one of standard adjuvant chemotherapy. 
With the above data, adjuvant chemotherapy for pancreatic 
cancer was justified. There are still debates for what is the best 
regimen or a drug as adjuvant setting. In 2016, adjuvant S-1, an 
oral fluorouracil prodrug was evaluated for adjuvant chemo-
therapy with Japanese patients.16 In this study, S-1 showed 
remarkable superiority to gemcitabine monotherapy in overall 
survival (46.5 vs. 25.5 months, HR 0.57; 95% CI 0.44–0.72; 
p<0.001). Even though the authors concluded that S-1 rather 
than gemcitabine should be the standard adjuvant chemo-
therapy after surgery of pancreatic cancer, it should be validated 
for ethnic difference to S-1 in future. In 2017, the final data of 
ESPAC-04 trial was published. In this study, a total of 730 
patients were randomized to adjuvant chemotherapy with 
gemcitabine ± capecitabine.17,18 The overall survival of 
gemcitabine/capecitabine group was 28.0 months and 25.5 
months in gemcitabine monotherapy group (HR 0.82; 95% CI 
0.68–0.98; p=0.032). More recently, the results from the multi-
center, randomized PRODIGE24/CCTGPA.6 French-
Canadian trial was reported. At a median follow-up of 34 
Table 1. Summary of clinical trials of adjuvant chemotherapy for pancreatic cancer




GITSG11,12 43 Observation 5-FU/RT + 5-FU 10.9 vs. 21.0 0.03
ESPAC-113 289 Observation 5-FU/LV 15.58 vs. 20.1 0.003
CONKO-00114 368 Observation Gemcitabine 20.2 vs. 22.1 0.06
ESPAC-315 1,149 5-FU/LV Gemcitabine 23.0 vs. 23.6 ns
JASPAC 0116 385 Gemcitabine S-1 25.5 vs. 46.5 <0.0001
ESPAC-417,18 732 Gemcitabine Gemcitabine/
Capecitabine
25.5 vs. 28.0 0.035
PRODIGE/CCTGPA.619 493 Gemcitabine mFOLFIRINOX 35.0 vs. 54.4 0.003
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months, disease free survival was significantly better with 
mFOLFIRINOX (21.6 vs. 12.8 months, HR 0.58; 95% CI 
0.46–0.73; p<0.001), as was overall survival (54.4 vs. 35 months, 
HR 0.64; 95% CI 0.48–0.86; p=0.003).19
Based upon currently available data, gemcitabine ± 
capecitabine or mFOLFIRINOX can be considered as the first 
choice of adjuvant chemotherapy for the patients of resected 
pancreatic cancer. However, there is still a large proportion of 
patients with poor response to the above chemotherapy. So, 
pretreatment response prediction models for personalized 
treatment such as patient derived tumor organoids or condi-
tionally reprogrammed cell culture should be more investi-
gated.20
2) Neoadjuvant chemotherapy
As already mentioned, pancreatic cancer is notorious for 
high risk of recurrence after surgery even in cases of very early 
staged cancer. Furthermore, the potential risk of complications 
with relatively aggressive surgery such as Whipple’s operation 
frequently prevent the patient from receiving adjuvant chemo-
therapy. These situations are the reason why neoadjuvant 
therapy should be considered in specific situations of pancreatic 
cancer. However, because powered randomized trials are insuf-
ficient, long-term outcome of neoadjuvant therapy was found 
through phase II trials and retrospective database analyses 
(Table 2).
In resectable disease, it is examined, an observational retro-
spective study analyzed by propensity score matching in 15,237 
patients with resected pancreatic cancer. It showed that those 
who received neoadjuvant therapy had better overall survival 
than those who received upfront resection (median survival 26 
months vs. 21 months, respectively; HR, 0.72; 95% CI 
0.68–0.78; p<0.01).21 Recently, SWOG S1505 trial is under way, 
which is a randomized phase II study intended to choose the 
most promising perioperative regimen (mFOLFIRINOX vs. 
gemcitabine/nab-paclitaxel [GnP]) for resectable pancreatic 
cancer.22 From 2015 to 2018, 147 patients were enrolled, but 
42/147 (29%) were ineligible at central radiology review. Follow 
up for overall survival is ongoing.
In borderline resectable disease, whether neoadjuvant 
therapy is better than upfront surgery plus adjuvant chemo-
therapy, and what is the best regimens to use in the borderline 
neoadjuvant setting are debated topics. But several studies 
suggest that neoadjuvant therapy with FOLFIRINOX are an 
auspicious approach in patients with borderline resectable 
disease.23-25 
3) Palliative chemotherapy
About more than half of the pancreatic cancer patients are 
diagnosed with metastatic disease. Consider unresectable status 
of locally advanced pancreatic cancer, more than two third of 
all pancreatic cancer patients should be treated with systemic 
anti-cancer therapies with palliative aims. But pancreatic cancer 
is one of the most resistant cancers to chemotherapy. It makes 
most novel drugs ineffective in so many clinical trials for 
pancreatic cancer. In real world, there are some auspicious 
signs for advanced pancreatic cancer such as introduction of 
relatively effective chemotherapeutic regimens or drug. 
Table 2. Summary of clinical trials on neoadjuvant therapy with resectable pancreatic cancer
Author Patients Therapy Resection rate (%) R0 rate (%)
Median survival 
(months)
Palmer et al.60 (2007) 24 Gemcitabine 9/24 (38) 6/8 (75) 9.9
26 Gemcitabine + Cisplatin 18/26 (70) 12/16 (75) 15.6
O’Reilly et al.61 (2014) 38 Gemcitabine + Oxaliplatin 27/38 (71) 20/27 (74) 27.2
Golcher et al.62 (2015) 33 Surgery 23/33 (70) 16/33 (48) 14.4
33 Gemcitabine/Cisplatin + Radiation 19/33 (58) 17/33 (52) 17.4
Casadei et al.63 (2015) 20 Surgery 15/20 (75) 5/20 (25) 19.5
18 Gemcitabine + Radiation 11/18 (61) 7/18 (39) 22.4
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(1) First line chemotherapy
Since the report by Burris et al.26 in 1997, chemotherapy for 
advanced pancreatic cancer had the first turning point. In their 
study, gemcitabine monotherapy showed a modest survival 
gain over the treatment with 5-FU and clinical benefit in terms 
of pain relief and weight gain. The success of gemcitabine for 
advanced pancreatic cancer facilitated so many clinical trial 
based on combination therapy with gemcitabine. However, 
during the last 20 years, very few phase III trials showed positive 
data. NCIC CTG PA.3 trial showed that erlotinib (inhibitor of 
EGFR tyrosine kinase) plus gemcitabine was superior to 
gemcitabine alone, statistically significant improvements 
in overall survival (6.24 vs. 5.91 months; HR, 0.82; 95% CI 
0.69–0.99; p=0.038), which is phase III, double-blind, placebo-
controlled trial for 569 patients with advanced or metastatic 
pancreatic.27 Even though the survival gain is so marginal, this 
trial was the first study showing positive data with combination 
of gemcitabine and target agent. 
In 2010s, two important studies provided another turning 
point in chemotherapy for advanced pancreatic cancer. In 
2011, Conroy et al.9 reported results of the randomized phase 
III PRODIGE trial evaluating FOLFIRINOX vs. gemcitabine in 
patients with metastatic pancreatic cancer. The overall survival 
was 11.1 months in the FOLFIRINOX group and 6.8 months 
in the gemcitabine group (HR 0.57; 95% CI 0.45–0.73; 
p <0.001). Though, because of the higher rate of toxicity, it 
remains a treatment indicated for fit patients with good perfor-
mance status. More recently, in 2013, Von Hoff et al.10 reported 
the data of phase III randomized clinical trial with GnP versus 
gemcitabine monotherapy for metastatic pancreatic cancer 
patients. They recruited 861 chemo-naïve patients with 
metastatic pancreatic cancer. The randomized trial showed that 
GnP was superior to gemcitabine alone in overall survival (8.7 
months vs. 6.6 months; p<0.0001; HR, 0.72).10 In 2017, our 
group also performed retrospective cohort study to evaluate 
this combination for Korean patients because the MPACT trial 
included on 2% of Asian ethnic group.28 In our data, the 
median overall survival was 12.1 months and 8.4 months of 
progression free survival.
In terms of which is better between FOLFIRINOX and GnP, 
there is no direct comparative prospective data. However, 
recently, Cho et al.29 reported that there was no difference in 
survival gain (overall survival 10.7 in FOLFIRINOX vs. 12.1 
months in GnP; p=0.157). The choice of first line treatment 
between both regimen should be based on not only the patient's 
performance status but also the plan for the 2nd line or rescue 
therapy after failure of first line therapy.  
(2) Second line or rescue chemotherapy
Although the advance in the first line chemotherapy for 
advanced pancreatic cancer, most of patients receiving the first 
line chemotherapy will be enfaced with cancer progression. So, 
rescue or 2nd line chemotherapy should be considered.30 
However, there are very limited data for 2nd line chemotherapy 
for advanced pancreatic cancer. Before introduction of 
NAPOLI-1 trial, numerous small sized clinical trials were 
published. In 2014, the CONKO-003 phase III trial presented the 
OFF regimen including oxaliplatin, folic acid and 5-FU, as an 
effective 2nd line chemotherapy after gemcitabine refractory 
treatment, demonstrating significant improvement in overall 
survival when compared with 5-FU/leucovorin (5.9 vs. 2.9 
months; HR 0.66; 95% CI 0.48–0.91; p=0.01).31 In 2018, our 
group also reported a single arm phase II study with modified 
FOLFIRINOX regimen for 2nd line chemotherapy.32 This study 
showed an acceptable toxicity profile and promising efficacy as a 
second-line treatment for gemcitabine-refractory unresectable 
pancreatic cancer. Total 48 patients were enrolled in this study, 
and the median PFS was 5.8 months (95% CI 3.7–7.9) and 
median overall survival was 9.0 months (95% CI 6.4–11.6).
 In 2016, the NAPOLI-1 phase III randomized trial with 
patients with metastatic pancreatic cancer who previously 
received gemcitabine-based therapy was reported. In this study, 
a total of 417 patients were randomized to receive the nano-
liposomal irinotecan monotherapy, 5-FU/leucovorin, or both. 
Both of progression free survival and overall survival of nano-
liposomal irinotecan with 5-FU/leucovorin group were signifi-
cantly improved (progression free survival, 3.1 vs. 1.5 months; 
HR 0.56; 95% CI 0.41–0.75; p<0.001, overall survival, 6.2 vs. 
4.2 months; HR 0.75; p=0.042). 
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2. Future’s perspective of chemotherapy for pan-
creatic cancer
1) Targeted therapies
Because of the heterogeneous environment of pancreatic 
cancer and complexity of stromal interactions, few targeted 
therapies succeed in clinical trials compared to standard 
treatment. As already mentioned, erlotinib plus gemcitabine 
was the only exception that showed statistically significant (2 
weeks) improvement in overall survival.27 Although, most of 
the studies on targeted therapies failed during phase II/III trials, 
numerous phase I/Ib studies are still ongoing.
(1) PARP inhibitors 
Up to 4% to 7% of pancreatic cancers arise in the setting of 
an inherited mutation in the breast cancer susceptibility 
(BRCA) 1 or 2 genes.33 In the POLO trial, 154 patients with 
germline BRCA-mutated metastatic pancreatic cancer that had 
not progressed during at least 16 weeks of first-line platinum-
based chemotherapy were randomly assigned to olaparib 
(PARP inhibitors) or placebo.34 Maintenance olaparib was 
associated with a significant improvement in PFS (7.4 vs. 3.8 
months; HR 0.53; 95% CI 0.35–0.82; p=0.004) than placebo. 
Based on these results, we now can consider olaparib as mainte-
nance therapy for those with advanced BRCA or PALB2 
germline-mutated pancreatic cancer who did not experience 
progression after initial platinum-containing therapy.
2)  Immunotherapy including cell therapy, immune check 
 point inhibitor
Immune-checkpoint-inhibitor antibodies is a new treatment 
option, which inhibit the interactions between immune cells 
and antigen presenting cells, including tumor cells.35 One of 
immune-checkpoint–inhibitor antibodies, pembrolizumab, 
which blockades PD-1, may be susceptible in tumors with 
mismatch repair deficiency.36 Pembrolizumab, anti-PD-1 
receptor antibody, blocks the interaction with its ligands, 
PD-L1 and PD-L2.36 And then, pembrolizumab improves 
antitumor immune response.36 It is showed that ORR was 62% 
among 6 pancreatic cancer patients in a phase II study in 
Table 3. Select immunotherapy trials in pancreatic cancer64
Category Targets ClinicalTrials.gov Identifier
PARP inhibitor + immunotherapy PARP, PD-1, CTLA-4 NCT03404960
Chemotherapy + immune agonists and antagonists Chemotherapy, CD40 agonist, anti-PD-1 NCT03214250




Matrix-targeted drugs +   immunotherapy PEGPH20*, PD-1 NCT03481920
NCT03193190
NCT03634332
Myeloid inhibitors + immunotherapy PD-1, CSF1R*
PDLA, CFS1R*
Cyclophosphamide, GVAX, PD-1, CSF1R*
Nab-paclitaxel, gemcitabine, BTK






Vaccines + immune checkpoint inhibitors CRS-207*, PD-1, CTLA-4, GVAX
Cyclophosphamide, GVAX, PD-1
Cyclophosphamide, GVAX, PD-1, CSF1R*





Radiation + immunotherapy PD-1, radiotherapy
PD-1, CTLA-4, radiotherapy





*PEGPH20, pegvorhyaluronidase alfa; CSF-1R, colony-stimulating factor 1 receptor; CRS-207, liver attenuated listeria-encoding human mesothelin 
vaccine; IDO, indoleamine 2,3-dioxygenase.
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patients with 12 different mismatch repair deficiency advanced 
cancers, including pancreatic cancer.37 Even, 2 had complete 
response. Two major approaches affect to increase the impact 
of immunotherapy in pancreatic cancer, which are usually 
combined with chemotherapy. First, multitargeted strategies to 
stimulate antitumor T-cell responses are being studied. For 
example, in an ongoing clinical trial it is studied, a multi-drug 
regimen consisting of chemotherapy (e.g., GnP), CD40 agonist 
and anti-PD-1 (Table 3). In other strategies, the focus is on 
combining PD-1/PDL1 blockade with drugs that inhibit 
immunosuppressive mechanisms mediated by fibroblasts (e.g., 
FAK), matrix proteins (e.g., hyaluronidase), and myeloid cells 
(e.g., CSF1R, BTK CCR2, CXCR2) (Table 3). Second, immune 
based strategies are focused to enhanced responsiveness to 
chemotherapy. For example, CCR2 inhibitor which interrupts 
the immune-cell recruitment to tumors in the situation of 
cytotoxic stress, has shown effective activity in patients with 
locally advanced pancreatic cancer.38
As an immunostimulatory strategy for cancer therapy, 
radiation is combined with immunotherapy in pancreatic 
cancer (Table 3). Radiation has also affect increased expression 
of MHC class I on tumor cells and synergy with anti-CD40, 
anti-PD-1, and anti-CTLA-4.39,40
3. The role of radiation therapy for pancreatic 
cancer
In pancreatic cancer, radiation is usually used, concurrently 
combined with chemotherapy, gemcitabine- or fluoropyrim-
idine-based.41 Chemotherapy is used to increase the toxicity of 
radiation to tumor cells, as a radiosensitizer.41,42 To decrease 
local recurrence, radiation or chemoradiation are sometimes 
used for pancreatic cancer after resection. Radiation therapy 
(RT) in adjuvant or neoadjuvant settings has a goal to decrease 
local recurrence and increase the rate of a margin-negative 
resection, while minimizing the RT exposure to surrounding 
organs at risk.
1) Adjuvant chemoradiation
After resection, adjuvant RT may be considered in patients 
with a high likelihood of local recurrence (e.g., positive 
resection margins, lymph nodes).41,43 The role of radiation has 
not yet been clarified, and remains at studies.41 Updated 2020 
guidelines from the NCCN suggest chemotherapy alone 
(FOLFIRINOX, Gemcitabine + nab-paclitaxel) as the preferred 
regimen for adjuvant therapy, but they include induction 
chemotherapy followed by chemoradiotherapy as an option for 
Table 4. Randomized clinical trial of adjuvant chemoradiation therapy
Clinical trial Group Patients Median survival time (months) Survival rate (%)
GITSG11,12 Chemoradiation (5-FU) 21 21 14 (5 years)
Observation 22 10.9 4 (5 years)
Chemoradiation (5-FU) (additional) 30 18 46 (2 years)
EORTC65 Chemoradiation (5-FU) 110 24.5 51 (2 years)
Observation 108 19 41 (2 years)
ESPAC-1 (pooled data)66 Chemoradiation (5-FU) 175 15.5 -
Chemoradiation (-) 178 16.1 -
Chemotherapy (5-FU) 238 19.7 -
Chemotherapy (-) 235 14 -
ESPAC-1 (2×2)13 Observation 69 16.9 11 (5 years)
Chemotherapy (5-FU) 75 21.6 29 (5 years)
Chemoradiation (5-FU) 73 13.9 7 (5 years)
Chemoradiation + chemotherapy (5-FU) 72 19.9 13 (5 years)
RTOG 970444 5-FU chemoradiation 230 17.1 18 (5 years)
Gemcitabine chemoradiation 221 20.5 22 (5 years)
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adjuvant therapy.41 The Gastrointestinal Tumor Study Group 
has shown an advantage to adjuvant chemoradiation over 
observation after resection, but European Organization for 
Research and Treatment of Cancer reported no statistically 
significant differences between adjuvant RT and 5-FU versus 
observation, at median follow-up of 11.7 years.44 ESPAC-1 trial 
showed that adding radiation to adjuvant 5-FU chemotherapy 
may be rather harmful (Table 4).13,41 
2) Neoadjuvant chemoradiation
Retrospective analyses found that neoadjuvant chemoradiation 
is better than neoadjuvant chemotherapy in local control, but 
not in survival.45 In resectable disease, although there is an 
evidence that neoadjuvant therapy may make a better chance of 
margin-negative resection,46 there are still few randomized trials. 
So, some randomized trials (SWOG 1505 trial [NCT02562716], 
or [NCT01389440]) are ongoing. Only patients, who have poor 
prognostic factors (e.g., significantly elevated CA 19-9; huge 
primary tumors; large regional lymph nodes; excessive weight 
loss; extreme pain) but appear resectable, can consider neoad-
juvant therapy after biopsy confirmation.41
Recently, various kinds of radiation therapy were introduced. 
In RT modalities, there are stereotactic body radiation therapy 
(SBRT), intensity-modulated radiation therapy (IMRT), 
proton beam radiation therapy, charged particle therapy, and 
so on. First, SBRT, deriving from Gamma-knife, is advanced 
technique that increase dose to target while reducing exposure 
to surrounding healthy tissue.47-54 SBRT uses a variety of 
motion management techniques to account for tumor and 
normal tissue motion, permitting higher doses than conven-
tional RT to the tumor while minimizing the risk of injury to 
adjacent organs. Retrospective study in the patients with locally 
advanced pancreatic cancer (n=998) represented that patients 
with SBRT compared to patients with conventionally 
fractionated RT had better median overall survival (13.9 vs. 
11.6 months, respectively; p<0.001) and 2-year overall survival 
(21.7% vs. 16.5%, respectively; p =0.001).55 Also, IMRT, 
developed from 3-dimensional conformal radiotherapy 
(3D-CRT), is increasingly applied for treatment of locally 
advanced pancreatic cancer. In recent systematic review, IMRT 
was not superior to 3D-CRT at survival outcomes,56 but in 
IMRT, toxicities grade 3 or greater were fewer than in 3D-CRT 
(p=0.017). Besides, Proton beam radiation thearpy is one of 
external beam radiation therapy, using not X-rays but proton 
beams. Proton radiotherapy can reach the optimal dose to 
targets while significantly normal-tissue sparing.57 Charged 
particle therapy is one of the most advanced technologies in 
radiation therapy.58 Charged particle therapy deposits more 
energy selectively, maximizing the effect on cancer and 
minimizing the damage from surrounding healthy tissue. And 
then, it can reduce complications and improve recovery rapidly 
after treatment.59
CONCLUSION
Although innumerable treatments have been developed, not 
many have been effective in pancreatic cancer. Since 1990, only 5 
of over 30 phase III clinical trials involving 16,000 patients 
showed clinical benefit in terms of survival elongation. Chemo-
therapy is still the main therapeutic tool for pancreatic cancer, 
and in metastatic setting, FOLFIRINOX and Gem/nab-paclitaxel 
are the standard. As adjuvant chemotherapy, gemcitabine based 
treatment can be chosen as universally, and mFOLFIRINOX can 
be considered for patients with good performance statusa as 
adjuvant setting. In neoadjuvant setting, there are many things to 
be settled down including appropriate drugs or other modalities 
and definitions of the conditions. We look forward to a break-
through in pancreatic cancer. Not limited to one treatment, 
precision medicine with different combinations of treatments 
should be more investigated in pancreatic cancer.
요 약
췌장암은 현재 가장 위협적인 악성종양 중 하나로, 5년 
생존율이 10%밖에 되지 않는다. 이렇게 췌장암의 예후가 
불량한 데에는, 항암화학요법에 반응이 저조한 것과 조기 
발견을  위한  효과적인  방법의  부재가  주요한  이유로 
생각된다. 여러 치료 방법 중에서 수술적 절제만이 췌장암의 
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완치를 기대할 수 있다. 그러나 수술 후 재발률은 여전히 50% 
이상으로 높고, 절제 가능한 단계로 진단되는 환자의 비율은 
췌장암  환자  중  1 5 %  미만으로  현저히  낮다 .  그래서 
항암화학요법과 방사선 치료는 췌장암 치료에서 중요한 역할을 
하게 된다. 췌장암 치료 중에서, 전이성 췌장암에 폴피리녹스 
( F O L F I R I N O X )와  젬시타빈 /냅 -파클리탁셀 
(Gemcitabine/nab-paclitaxel)을 도입한 후에야 두 자릿수 
생존율을 기대할 수 있게 되었다. 또한 경계 절제 가능 췌장암과 
절제 가능 췌장암에서 동시 항암화학방사선요법을 포함한 선행 
항암치료법이 수술을 먼저 시행하는 치료 방법보다 우수하다고 
보고되었다. 최근에는 폴리아데노신 디프인산-리보오스 
중합효소(PARP) 억제제, 면역항암제 등 여러 표적제들이 
췌장암에 시도되고 있다. 이제 췌장암 치료에서 중요한 위치에 
있는 항암화학요법과 방사선 치료의 현황에 대하여 설명하고자 
한다.
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